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Background. Capturing service users’ perspectives can highlight additional and different concerns to those of clinicians,
but there are no up to date, self-report psychometrically sound measures of side effects of antipsychotic medications.
Aim. To develop a psychometrically sound measure to identify antipsychotic side effects important to service users, the
Maudsley Side Effects (MSE) measure.
Method. An initial item bank was subjected to a Delphi exercise (n = 9) with psychiatrists and pharmacists, followed by
service user focus groups and expert panels (n = 15) to determine item relevance and language. Feasibility and compre-
hensive psychometric properties were established in two samples (N43 and N50). We investigated whether we could
predict the three most important side effects for individuals from their frequency, severity and life impact.
Results. MSE is a 53-item measure with good reliability and validity. Poorer mental and physical health, but not psych-
otic symptoms, was related to side-effect burden. Seventy-nine percent of items were chosen as one of the three most
important effects. Severity, impact and distress only predicted ‘putting on weight’ which was more distressing, more
severe and had more life impact in those for whom it was most important.
Conclusions. MSE is a self-report questionnaire that identiﬁes reliably the side-effect burden as experienced by patients.
Identifying key side effects important to patients can act as a starting point for joint decision making on the type and the
dose of medication.
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Introduction
Medication side effects, especially for antipsychotic
medication, contribute to subjective ratings of mental
health (Hayhurst et al. 2015) and can result in discon-
tinuation or dose reduction by patients (Ashoorian
et al. 2014; Morrison et al. 2015) which may produce
multiple harmful effects. Side effects vary and include
severe weight gain, impotence, insomnia, chronic sed-
ation and a lack of concentration, all of which interfere
with daily life activities. Close monitoring is important
because they are associated with physical morbidity
and mortality, poor adherence, and stigma, as well as
a negative impact on quality of life. Joint decision-
making on medication dose, or whether the beneﬁts
outweigh the risks or consequences, would be greatly
enhanced if patients themselves were empowered to
measure side effects outside a face-to-face contact
(Morrison et al. 2016). Beneﬁts include improved adher-
ence and attitudes towards medication (Moncrieff et al.
2016) as well as prompt and appropriate intervention to
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minimise side-effect burden and prevent long-term
physical health problems (Bauml et al. 2016). Over and
above the health effects, such a measure could support
a dialogue about speciﬁc medication type, dose or dis-
continuation and so contribute to a positive therapeutic
relationship, which also has an effect on medication
adherence (Sendt et al. 2015).
Why do we need a self-report measure?
National audits of clinical records in UK mental health
services have found deﬁciencies in the quality and fre-
quency of recommended side-effect screening for
patients prescribed antipsychotics in both community
and inpatient settings (Paton et al. 2004; Taylor et al.
2004; Barnes et al. 2007). Observational studies
(Turner, 1993; Jordan et al. 1999) and survey reports
(Bennett et al. 1995; Gray et al. 2001) also found that,
in clinical practice, mental health nurses tend to monitor
only a limited number of antipsychotic side effects and
to rely on general questioning and observation to detect
medication-related problems. This data collection
method is inaccurate as patients tend to underestimate
adverse effects in response to such general questions
(Yusuﬁ et al. 2007; Cleary et al. 2012). The problems
are no fewer in the clinical scientiﬁc evidence.
Reviews of side-effect reporting conclude that most
studies used no published side-effect ratings scales
except for movement disorders (Pope et al. 2010) or
only assessed a limited range of effects (Longden &
Read, 2016). Spontaneous reporting of side effects
important to patients is probably scarce given the likely
misattribution of side effects to symptoms, forgetfulness
or embarrassment about raising intimate effects.
What should a measure include?
The comprehensive assessment of antipsychotic side
effects presents several challenges, one being the diver-
sity of potential problems, including anticholinergic
and metabolic side effects and adverse effects on the
motor, endocrine and cardiovascular systems. A recent
review (van Strien et al. 2015) recommends self-report
multi-domain scales to inﬂuence the clinical dialogue
and allow sensitive questioning and clinical observa-
tion to produce a comprehensive assessment and to
allow patients to report effects of importance to them
which differ (Morrison et al. 2012) or be complemen-
tary to those of clinicians (Patel & David, 2007;
Trujols et al. 2013).
Why involve patients?
We will not rehearse in detail the notion that patient
views are valid measures of treatment efﬁcacy as
there is plenty of evidence in the literature [e.g.
Angermeyer et al. (2011)] including new data on side-
effect reporting (Hayhurst et al. 2015). There is also
evidence that service users regard patient-reported
outcome measures (PROMs) as more appropriate and
relevant than observer-rated measures (Crawford
et al. 2011). PROMs are commonly used to measure
the suitability of, and satisfaction with, treatment and
therapies, including side-effect burden. However,
patients have rarely been involved in their develop-
ment. For instance, SMARTS, a pragmatic side-effect
checklist (Haddad et al. 2014), is based on the views
of psychiatrists and purports to be using lay language
and yet no patient was involved in its design. The
Glasgow Antipsychotic Side-effect Scale [GASS;
Waddell & Taylor (2008)] was built only on informa-
tion in the British National Formulary and decisions
on medical importance made by the authors. This
measure did include a patient focus group to agree
acceptability, although no information is provided
about whether the patients did ﬁnd the questions
acceptable. Given the evidence that patients have dif-
ferent priorities to clinicians, it is surprising that a
True Patient Valued and Generated Reported
Outcome Measure (PG-PROM) has not been devel-
oped. True PG-PROMs are those where patients are
speciﬁcally involved in the development of the scale
(including as researchers) as well as completing the
measure by self-report. In addition to the obvious
acceptability beneﬁts, they are also likely to cover a
wider list of patient valued side effects that may
drive adherence and treatment engagement. A side-
effect scale that includes such items will allow clini-
cians access to previously unrated side effects that
may predict treatment response.
The participatory methodology for the development
of True PG-PROMs is now well described [e.g. Rose
et al. (2011)]. Development includes psychometric
assessment especially given their current weaknesses
(Ashoorian et al. 2014; van Strien et al. 2015). For
instance, Wolters et al. (2009) report weak psychomet-
ric properties for the Drug Attitude Inventory [DAI;
Hogan et al. (1983)]. The Liverpool University
Neuroleptic Side Effect Rating Scale [LUNSERS; Day
et al. (1995) potentially overestimates antipsychotic
side-effect frequency (Wolters et al. 2009) and although
it did involve patients in its development and has good
psychometric properties (van Strien et al. 2015) is now
out dated. In addition to moderate psychometric prop-
erties (van Strien et al. 2015) most studies had small
samples affecting conﬁdence in the supporting data.
For instance, the GASS (Waddell & Taylor, 2008)
test-retest measure is based only on 17 respondents.
For personalised medicine, a psychometrically sound
measure would allow concurrent side effects from large
populations to aid the identiﬁcation of biomarkers of
treatment effects quickly. Our aim is to develop such a
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sound PROM of antipsychotic medication side effects
using innovative participatory methodology (Rose
et al. 2011) to capture the patient perspective and more
accurately reﬂect their priorities (Faulkner & Thomas,
2002; Trivedi & Wykes, 2002) which are likely to be dif-
ferent to those of clinicians. Identifying patient-valued
negative effects might then drive the development of
new treatments as well as the prescription of thosemed-
ications already proven to be efﬁcacious.
Method
Design
The study employed mixed methods with qualitative
approaches for measure generation and quantitative
methods to evaluate the psychometric properties. The
Maudsley Side Effects (MSE) measure were developed
in three phases: (1) generating the measure, (2) assessing
reliability andotherproperties and (3) evaluatingvalidity.
Participants
Seven psychiatrists with a psychopharmacology back-
ground and two pharmacists from the UK, USA and
Spain with a known expertise in side effects took
part in the Delphi exercise.
For all other parts of measure development, we
recruited participants with a clinical diagnosis of
schizophrenia (according to case records), who were
in touch with mental health services, aged 18–65
years and had taken antipsychotic, but not antidepres-
sant, medication for a minimum of a month. We
recruited participants from outpatient clinics, inpatient
units and clozapine clinics in three waves:
• sample 1 (N15) took part in the focus groups and the
expert panel;
• sample 2 (N43) completed the draft MSE on two
occasions, feasibility questionnaire and detailed
measures of clinical state;
• sample 3 (N50) completed the MSE and another
patient reported side-effect measure.
Ethical approval was given by the London Dulwich
Ethics Committee (12/LO/2034).
Measures
(1) Demographic and clinical data;
(2) Clinical state: (i) Brief Psychiatric Rating Scale
(Ventura et al. 1993), an interview measure identi-
fying mainly psychotic symptoms, and (ii) the
General Health Questionnaire [GHQ-12; Goldberg
(1992)] and the Short Form Health Survey
Version 2 [SF-36v2; Ware et al. (2000)], self-report
measures of general health with no questions relat-
ing to psychosis;
(3) GASS (Waddell & Taylor, 2008) a self-report meas-
ure of antipsychotic side effects;
(4) Feasibility questionnaire used in other measure
developments [e.g. Evans et al. (2012)], which
assesses accessibility, acceptability and interest.
Procedure
Phase 1: Generating the draft measure
(i) Delphi consultation: An initial bank of items was
drawn from three existing self-report side-effect
measures: The Antipsychotic Non-Neurological
Side-Effects Rating Scale [ANNSERS: (Yusuﬁ et al.
2005; Ohlsen et al. 2008)], GASS (Waddell & Taylor,
2008) and LUNSERS (Day et al. 1995). We undertook
a Delphi exercise to determine the relevance and
importance of each item based on up to date knowl-
edge of current antipsychotic medications. We fed
back initial itemratings andgroupmeans to eachpar-
ticipant who re-rated them. Following this consult-
ation, we recalculated the mean responses and used
them to determine important items to include.
(ii) Service user consultation: Two focus groups met to
discuss their experiences of antipsychotic medica-
tion side effects and to comment on the items
drawn from the Delphi exercise. Two service user
researchers, one with extensive experience of
using antipsychotic medication, ran the focus
groups. Each group was audiotaped, transcribed
and then analysed using nVIVO10. The comments
and themes generated a draft measure and a ser-
vice user expert panel commented on the content,
language and format.
Phase 2: Feasibility and item inclusion
Our expert panel of service users and pharmacologists
considered low frequency items from sample 2 meas-
ure completion for future retention. Feasibility ques-
tionnaire data determined acceptability.
Phase 3: Psychometric analysis
The measure will be used to generate discussion on
patient valued items but four total scores can be
extracted to summarise the information:
(a) Total side effects endorsed (range: 0–53).
(b) Total intensity by summing the 4-point Likert life
intensity items (refers to the selected side effects,
with range: 0–159).
(c) Total distress by summing the binary distress
items (refers to the selected side effects, with
range: 0–53).
(d) Total life-impact by summing the 4-point Likert life
impact items (refers to the selected side effects,
with range: 0–159).
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We conducted psychometric properties analyses at
both the item and subscale level. For the total scores,
parametric methods (Pearson’s correlation coefﬁcient
r and t test for the equality of means) and their non-
parametric analogues were used (Spearman’s rho and
Wilcoxon test, respectively) depending on whether
the scores were normally distributed.
We investigated different forms of both reliability
and validity. For reliability, internal consistency was
evaluated using Cronbach’s alpha (Cronbach, 1951).
For stability (test–retest reliability) sample 2 participants
completed the new measure twice within an interval of
6–8 days. We used Cohen’s kappa [κ; (Cohen, 1960)] to
assess item level agreement. For ordinal items,
weighted kappa [κw; (Cohen, 1968)] is reported and
we have used the Landis and Koch (Landis & Koch,
1977) interpretations (negative values no agreement,
>0.8 almost perfect agreement). We used correlation
coefﬁcients between the two time points and the
differences between the corresponding means when
evaluating the total scores.
We evaluated concurrent, content validity in both
samples 2 and 3. We assessed convergent and divergent
validity in sample 2 via the association of total MSE
scores with BPRS, GHQ and SF-36v2. We used the
GASS scale in sample 3 to estimate the convergent
validity and for criterion validity, we evaluated the
presence of a likely side effect (drooling) with the pre-
scription of clozapine in both samples. Finally, the
inter-correlations between the summary scores and
the effect of age and gender provided further evidence
towards the content validity of the MSE.
All analyses were conducted using SPSS 23 along
with irr (Gamer et al. 2010) and psych (Revelle, 2010)
packages in R 3.0.2.
Results
Participants
All samples had similar demographic characteristics.
(see Table 1). The median BPRS score of sample 2
was 45, which is close to the median score of 47.3
noted in individuals with established schizophrenia
(McCleery et al. 2014). Clinical state did not change
signiﬁcantly across the two time points (Web-
Table S1; r = 0.85 p < 0.001; median scores: T1 45, T2
48 and 46% with 0 change).
Phase 1: Measure generation
The Delphi exercise identiﬁed items of: (i) uncertain val-
idity, (ii) detected only by observation or (iii) duplication
and these itemswere removed.Other itemswere clariﬁed
and additional ones related to newer antipsychotic med-
ications added. Following these changes, the research
team (including the service user researchers) reworded
all questions into a simple, easy-to-read format.
Prompted by the list of side-effects and following a
discussion of personal experiences, focus group partici-
pants removed a duplicate item, generated eleven new
items and advised on presentation and scaling. The
expert panel (n = 6) added one new item and a com-
ments box and considered the questionnaire both com-
prehensive and the right length.
At this point, there were 54 items each with three
ratings: intensity (0-not at all, 1-mild, 2-moderate,
3-severe), distress (yes or no) and life impact (4-point
Likert scale). Two additional items noted the most
important three side effects and the balance of beneﬁts
of taking medication.
Phase 2: Feasibility and draft items
In sample 2, the side effects reported most often (see
Web-Table S2) were ‘feel tired’ (77%), ‘put weight on’
(70%), ‘passing urine’ (67%), ‘thirsty’ (67%) and
‘memory issues’ (65%) and very similar results were
obtained in the replication group (sample 3 Web-
Table S2). One low-frequency item was dropped as it
had less value and was difﬁcult to self-report leaving a
53-item scale to assess psychometric properties. MSE has
a Flesch reading ease score of 103 where scores of 90–
100 are regarded as ‘very easy’ to understand (Flesch,
1948).MSEwas acceptable to the vastmajority of the sam-
ple (99% found it easy to understand, 93% easy to com-
plete and 93% an appropriate length). Three service
users disliked completing the measure and 20% found
some questions distressing, which were those associated
with sensitive intimate issues – sexual problems, enuresis
and constipation. It takes about 15 min to complete.
Psychometric analyses
Descriptive data
The mean total number of side effects reported was 21
out of 53. Intensity, life impact and distress scores were
skewed towards the lower end of the scale (see Web-
Table S3). As expected a higher side-effect burden cor-
related with more distress and life impact and all these
correlations were statistically signiﬁcant (see Web-
Table S4). As anticipated, neither age nor gender
(Web-Table S5) affected side-effect endorsement (p >
0.1 in all cases) and all these results were replicated
in sample 3 (Web-Tables S6 and S7).
Reliability
Cronbach’s alpha for the total side-effects score was
0.96, indicating very high correlations between items.
At the item level, the weighted Kappa coefﬁcient indi-
cated at least fair agreement for intensity items. Non-
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signiﬁcant coefﬁcients emerged only for ‘ﬁts’, ‘rash’
and ‘catatonia’ side effects, probably due to their low
frequency (see Web Table S6). At the subscale level, all
scores were highly correlated (0.81–0.96) between the
two time points and there were no statistically signiﬁ-
cant differences in the mean scores, indicating the
instrument’s good test–retest reliability (see Web
Table S2). Symptoms did not affect reliability as it
was stable for both high and low BPRS scorers [high
scorers (above the median – 45): ρ = 0.85, p < 0.001;
low scorers (below median): ρ = 0.94, p < 0.001].
Validity assessment
(i) We established concurrent convergent validity by
comparing the side-effects summary scores with
clinical state measures (sample 2). As expected, a
greater number of side effects were related to
poorer measures of general mental health (GHQ,
SF-36 mental component) and physical health
(SF-36) as items overlap (see Table 2).
But our speciﬁc psychosis mental state measure
did not have overlapping items so should not be
related. We investigated side-effect reporting in
the low and high BPRS scorers and found evidence
of discriminant validity as the two BPRS groups did
not differ in side-effect reporting (total side effects
mean 22.7 v. 19.3; Z = 0.86, p = 0.39; intensity
median 43.1 v. 29.7 Z =−1.26, p = 0.21; distress
median 29 v. 19; Z =−0.95, p = 0.35). However,
high BPRS scorers, as expected, reported signiﬁ-
cantly higher life impact (median 9 v. 2; Z =−2.858,
p = 0.004) given that higher symptom levels plus
the side effects are likely to have the highest impact
on everyday life.
(ii) We established concurrent convergent validitybetween
GASS and MSE (sample 3; Table 3). At the similar
item level, the agreement in endorsement varied
from 70% to 90%. For distress agreement ranged
from 73% to 100%. All weighted kappa coefﬁcients
were signiﬁcant and indicated fair to substantial
agreement. At the total score level (all items included
in both scales), the MSE and GASS subscales were
highly correlated (total side effects: r = 0.8, intensity:
r = 0.8 and distress: r = 0.7, p < 0.001 in all cases).
For concurrent criterion validity, we measured the effects
of a side effect most often associated with Clozapine
prescription, drooling. These results were replicated
in sample 3 (N50), and those prescribed Clozapine
(N30; 60%) were more likely to report drooling and
when they experienced drooling it was more intense
compared with those prescribed other medications
[(i) frequency of reporting 80% v. 35%; χ2 = 10.314, df
Table 1. Demographic and clinical characteristics
Phase 1 (sample 1) Phases 2 and 3
Focus group and expert panel Sample 2 (N = 43) Sample 3 (N = 50)
N % N % N %
Gender
Men 3 20 27 63 28 56
Women 12 80 16 37 22 44
Ethnicity
White 12 80 14 32 18 36
BME 3 20 29 68 32 64
Range Mean (S.D.) Range Mean (S.D.) Range Mean (S.D.)
Age (years) 29–56 41.2 (8.7) 24–64 45.8 (9.9) 28–64 45.7 (8.9)
BPRS 26–73 46.0 (12.9)
GHQ 0–23 11.1 (5.4)
SF36-physical 21–64 44.7 (10.1)
SF36-mental 25–65 44.0 (10.2)
Table 2. Correlation coefﬁcients between theMSE scores and SF-36
and GHQ scores
SF-36 Physical SF-36 Mental GHQ
r p value r p value r p value
Total effects −0.4 0.003 −0.5 0.001 0.5 <0.001
Intensity −0.5 <0.001 −0.5 <0.001 0.5 0.001
Life Impact −0.7 <0.001 −0.4 0.009 0.5 0.004
Distress −0.4 0.008 −0.4 0.019 0.2 0.219
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= 1, p = 0.001; higher intensity when reported, median:
1.6 v. 0.7; Mann–Whitney U = 157.5, p = 0.003]. The pat-
tern of results was the same for sample 2 although
there were fewer people prescribed clozapine (N9;
21%). We tested for differences in distress and life
impact after merging the two samples but no statistic-
ally signiﬁcant differences emerged (χ2 = 0.570, df = 1, p
= 0.450) or life impact (median: 1 in both cases; Mann–
Whitney U = 183.0, p = 0.130) suggesting that drooling
is distressing and affects life, whichever drug pro-
duced the effects.
The most important side effects
The pattern of most important side effects was the
same samples 2 and 3 with only one difference, drool-
ing was chosen more often in sample 3 selecting this
item (21% v. 11.6%; χ2 = 5.488, df = 1, p = 0.019) prob-
ably because it contained more people prescribed
clozapine.
Participants (merged sample N93) endorsed 42 of
our 53 items as one of the three most important side
effects (see Web Table S8) providing further validity
for the breadth of scale items. The three most often
mentioned were feeling tired, drooling and putting
on weight selected by 16–23% of the total sample.
The remaining items were selected by <9% suggesting
that what bothers an individual is idiosyncratic.
What determines an individual’s choice of the most
important side effect?
A participant’s choice did not follow the endorsement
frequency. For instance, 62% identiﬁed memory
problems, but they were only mentioned as ‘most
important’ by 16%. As many ‘most important’ items
were low frequency, we concentrated on the side
effects most frequently reported – feeling tired, drool-
ing and putting on weight. Choosing tiredness or
drooling was not related to how an individual rated
its severity, distress or life impact. However, for ‘put-
ting on weight’ those who mentioned it as most
important also rated it as more severe (60% v. 29.4%,
χ
2 = 6.384, df = 1, p = 0.041), having more life impact
(70% v. 20.4%, χ2 = 12.432, df = 1, p = 0.006) and being
more distressing (90% v. 27.5%, χ2 = 13.926, df = 1, p <
0.001).
Discussion
We derived the new measure from the published lit-
erature on antipsychotic side-effect rating scales,
with the participation of experts from psychiatry
and pharmacy, service users (including service user
researchers) and methodologists. We adopted this
process in order to ensure that we captured the sorts
of side effects that service users’ value. In addition,
we also had the advantage of updated knowledge
on the side effects of newer antipsychotic medications.
Our ﬁnal measure consists of 53 side-effect items, each
with three associated questions regarding intensity,
distress and life impact. The measure covers a range
of antipsychotic side effects, including metabolic, sex-
ual and anticholinergic effects. Items are in the words
used by patients so that they are easily understood.
The ﬁnal MSE is a measure of an individual’s side-
effect burden, not a checklist of the drug-related phe-
nomena present.
Table 3. Similar Item level agreement assessed for items with at least 15 individuals reporting on the MSE
Side effect (item number
GASS-MSE)
Intensitya Existence Distress
N
Weighted
kappa (p)
N present
GASS (%)
N present
MSE (%) % kappa (p) N % kappa (p)
Felt zombie (2–40) 50 0.6 (<0.001) 14 (28) 16 (32) 88 0.7 (<0.001) 12 100 1.0 (0.001)
Dizzy (3–20) 50 0.6 (0.003) 25 (50) 20 (40) 74 0.5 (0.001) 16 75 0.5 (0.049)
Heartbeat (4–14) 50 0.5 (<0.001) 20 (40) 20 (40) 76 0.5 (<0.001) 14 79 0 (0.672)
Shaky (6–15) 49 0.6 (<0.001) 15 (30) 15 (30) 84 0.6 (<0.001) 11 100 1.0 (0.001)
Restless (7–41) 49 0.8 (<0.001) 21 (42) 20 (40) 90 0.8 (<0.001) 18 94 0.9 (<0.001)
Drooling (8–19) 50 0.7 (<0.001) 29 (58) 31 (62) 84 0.7 (<0.001) 26 85 0.6 (0.001)
Slow move (9–24) 50 0.5 (0.001) 22 (44) 27 (54) 70 0.4 (0.003) 17 82 0.6 (0.005)
Blurry vision (11–21) 47 0.8 (<0.001) 21 (42) 20 (40) 89 0.8 (<0.001) 18 78 0.5 (0.034)
Dry mouth (12–5) 48 0.6 (0.001) 21 (42) 22 (44) 81 0.6 (<0.001) 17 77 0.2 (0.432)
Feel sick (14–42) 50 0.6 (<0.001) 16 (32) 16 (32) 84 0.6 (<0.001) 12 83 0.6 (<0.001)
Weight (22–23) 39 0.4 (<0.001) 24 (48) 23 (46) 92 0.8 (<0.001) 22 73 0.4 (0.070)
aConsidered if the item was endorsed on both scales.
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The measure was acceptable and feasible, and
demonstrated strong psychometric qualities for both
reliability and various forms of validity in its self-
report form. Importantly, the severity of psychotic
symptoms did not affect side-effect endorsement sug-
gesting it is appropriate for those who are more acutely
unwell. This is the ﬁrst time a measure, acceptable to
service users and with high-quality psychometric
data have been developed and it therefore overcomes
the problems of previous measures. The MSE follows
the recommendations of recent reviews in being more
comprehensive (multi-domain) (van Strien et al. 2015)
with strong psychometric and appropriate measures
(Wolters et al. 2009; Stomski et al. 2016). Some side
effects may look different to those described in other
measures (e.g. feel like a zombie), but this is because
the items were generated by patients themselves.
How does our measure differ from others?
Apart from updating the content (a constant process)
we adopted a participatory approach with input
from clinicians and, importantly for a self-report meas-
ure, service users. We are not the ﬁrst to involve ser-
vice users in the development of a side-effect
measure as the authors of the GASS (Waddell &
Taylor, 2008) also consulted them but only in one
focus group to rank the item acceptability. Our
involvement was more extensive, and produced
noticeable changes, including adding in side effects
that were valued by them and considered to be quali-
tatively different, e.g. items relating to sleep or tired-
ness were divided into feeling tired, sleeping too
much, difﬁculty staying awake, hard to fall asleep
and hard to get out of bed. It is notable that GASS is
the only measure to include distress (as we did) but
our measure is the ﬁrst to include life impact. Many
measures (e.g. LUNSERS; Day et al. 1995) also use
red herring items but in the initial review by our
psychiatry and pharmacy experts many of these red
herrings were either subsequently indicated as an
actual side effect or were so transparent that they
were likely to irritate service users. Hence, we
excluded them from the beginning.
The issue of length as well as breadth produces dif-
ferent responses from clinicians and patients. The view
from clinicians is that a short questionnaire is prefer-
able so most clinician generated scales are often <20
items. In contrast, scales involving patients, e.g.
LUNSERS and SRA (Day et al. 1995; Wolters et al.
2006) are the longest but even so LUNSERS was picked
as a favoured outcome by patients (Crawford et al.
2011). A balance needs to be struck, but multi-domain
scales are likely to be longer if they are to be compre-
hensive. The fact that so many different items were
mentioned in the three ‘most important’ side effects
suggests that it would be hard to reduce the scale.
Despite being twice as long as another comparable
measure MSE only takes about 15–20 min to complete
and importantly is acceptable to service users.
Which side effects are important to patients?
The choice of the ‘most important’ side effects seems to
be idiosyncratic and it would be difﬁcult to determine
them from their frequency. Severity, distress nor life
impact predicted the endorsement of two of the top
three most important items, tiredness and drooling.
However, ‘putting on weight’ was related to distress
and life impact, replicating a recent survey (Ashoorian
et al. 2015) where it was the most ‘bothersome’ side
effect.
Clinicians are obviously concerned about side effects
that have health consequences, but these are often only
obvious on physical examination, with blood tests and
detailed targeted questions. No self-report scale can be
a substitute for such clinical examination. For clinical
use, the opportunity for service users to describe the
most important side effects, as well as listing those pre-
sent will enable a more informed discussion on redu-
cing patient-valued unwanted effects. These may be
effects with a large life impact, but do not necessarily
have medical consequences, at least in the short term,
and therefore in a clinical encounter they could be
overlooked. Changes in the perceived value of side
effects over time may reﬂect changes, not in medica-
tion dose or tolerability, but in the process of recovery.
For instance, if you are staying at home a slight shaki-
ness might not be as important to a service user, but
the importance of this side effect will change if the ser-
vice user then needs to use a smartphone or computer
for work. These changes need to be captured, as MSE
does, as they highlight areas for clinical discussion
about the risks and beneﬁts of medications, which
can improve the therapeutic alliance. These discussions
are also vital because recent studies suggest that poor
adherence in the short term may be only loosely asso-
ciated with longer lasting negative attitudes which are
inﬂuenced by side-effect burden (Hui et al. 2016).
Patient-value for negative effects is also important
for treatment development. Currently, patient perspec-
tives are used only at the end of the development, but
perhaps drug developers can use evidence of side-
effect value in considering which of several com-
pounds to take into phase 1 or 2. The result of such
developments might be a shift in patient involvement
not to the dissemination and adoption sections of the
translational pipeline but much closer to the bench so
research is driven also by the patient perspective
(Callard et al. 2012).
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We hope that MSE will enhance clinical engagement,
an important issue for treatment adherence and recov-
ery. MSE can also provide information over time on
the effects of dose changes on patient rated important
items and will also allow tracking of side-effect burden
so providing clinical utility too.
Strengths and limitations
A study strength is our service user input and our
extensive testing of psychometric properties to demon-
strate good reliability and validity. This measure will
not substitute for clinical observation, as it is limited
to side effects that are easily self-reported. Medically
important effects will require clinical observation.
Although we found no relationship between symp-
toms of the disorder and side-effect endorsement,
some side effects endorsed might not be related to
medication but may be related to unpleasant effects
of the disorder, e.g. agitation rather than drug-induced
akathisia. Alternatively, a side effect may not be drug
related, but may be related to an underlying physical
cause requiring further investigation of the aetiology.
We therefore emphasise that this measure is one tool,
but not the only tool, to inform decisions about medi-
cation; it is an adjunct to, but not a replacement for,
joint decision-making. We included a group of service
users who were middle aged and drawn mainly from
outpatient services and so future studies need to inves-
tigate both older and younger groups and inpatients
who may have slightly different views on the import-
ance of some side effects.
Clinical uses
We consider this measure a valuable tool to support
clinicians in their discussions and negotiations about
medications. These discussions may be aimed at chan-
ging the type or dose of medication, or to discuss
potential discontinuation. Sometimes side effects are
not reported in a clinical encounter because they are
considered unavoidable or for which there are no
obvious solutions. They may not also be reported
because the service user is embarrassed to discuss
them. MSE should facilitate such encounters and
allow both clinicians and service users to monitor
the effects of dose changes or changes of drug on
side effects over time. We suggest that this measure
ought to be completed at least once per year and
more frequently to monitor speciﬁc changes in medi-
cation. We will be including this measure on a patient
portal – myhealthlocker™ – so data on side effects can
also feed into information on the efﬁcacy of medica-
tions across groups of patients and within particular
services.
Conclusion
Wehaveproduceda self-report side-effect burdenmeas-
ure for antipsychotic medication, which allows patients
to reﬂect on the effectsmost important to them. It is feas-
ible, acceptable and has good psychometric properties.
This is the sort ofmeasure voted as preferred by patients
(Crawford et al. 2011), and which has the chance to sup-
port clinical discussions, improve therapeutic engage-
ment, in addition to allowing clinicians an insight into
their patients’ changing perspectives on side effects
that have a large life impact.
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